Markus Sieger – CEO, Polpharma
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights…
Address: Polpharma
Trade Office
Bobrowiecka 6
00-728 Warsaw
Poland,@ Global
Tel: +48 22 364 61 00
Web: http://www.polpharma.pl/en/about-us/
Polpharma SA belongs to the select group of leaders in the pharmaceutical industry in Poland. For 75 years it has enjoyed the trust of patients, doctors and business partners.
Polpharma was established in 1935. In 2000 it was privatised with the participation of exclusively Polish capital. Polpharma’s strength is the combination of many years of experience with modern technologies and the highest standards of management.
Polpharma is currently the largest Polish manufacturer of generic drugs and pharmaceutical substances. It produces a wide range of prescription drugs and drugs used in inpatient care. The company specialises in preparations used in cardiology, gastroenterology and neurology. A significant part of Polpharma’s portfolio contains also OTC drugs.
Polpharma is the majority shareholder in Medana Pharma S.A. from Sieradz, which is the leader in the area of manufacture of paediatric drugs and vitamin preparations in modern forms. Medana’s portfolio includes also dermatological drugs and drugs used in motor organ disorders, as well as dietary supplements.
In July 2010, Polpharma took over from Bioton SA the part of the company dealing with the manufacture and sale of antibiotics.
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights…
Liana Maksyoutova, country manager of Polpharma Ukraine, provides insights into the impressive transformation of the Ukrainian affiliate that she has fostered since inheriting its reins in 2012 and how she…
Polpharma , Poland’s role model and largest Polish manufacturer of drug products and active pharmaceutical ingredients, has pushed the Polish boundaries with the objective to become the fastest growing regional…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
“Innovation is about bringing new chemical compounds on the market; but it is also, and sometimes even more, to continue the therapeutic development of the drugs which are already there”…
Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming…
Medtronic’s country director brings some interesting perspectives on the differences between the pharma and medical device regulations in Poland by saying: “the medical device industry is discriminated against, as we…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with…
“In this very competitive environment, patents give companies an edge; this is why we must maintain innovative breakthroughs in our industry. This will then allow us to compete more efficiently…
“The overall Polish healthcare system is quite good. Of course, there are flaws, but Poland is equipped to treat almost any disease. The flaws in the system stem from historically…
In a world where diabetes increasingly more common, Poland has not been spared, with 2.5 million diabetic patients currently, and with a further 750,000 still unaware of their condition. In…
Cezary Sledziewski, Executive Director of PZPPF, discusses the pros and cons of Poland’s catching up with EU’s rising standards. He argues: “No one currently knows exactly how much these costs…
Polpharma , Poland’s role model and largest Polish manufacturer of drug products and active pharmaceutical ingredients, has pushed the Polish boundaries with the objective to become the fastest growing regional…
See our Cookie Privacy Policy Here
